---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-015882"
form_type: "8-K"
ticker: null
cik: "0001673772"
company_name: "RAPT Therapeutics, Inc."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:33:48.301958+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# RAPT Therapeutics to be acquired by GSK for $58/share in all-cash tender offer

## Summary
- GSK subsidiary will commence tender offer at $58.00 per share in cash within 10 business days.
- Company termination fee set at $78.4M; reverse termination fee payable by GSK at $100.8M.
- Support agreements cover ~0.25% of outstanding shares; Board recommends tender.
- Transaction expected to close by July 19, 2026, subject to HSR clearance and majority tender condition.

## SEC filing metadata
- accession: 0001193125-26-015882
- form_type: 8-K
- cik: 0001673772
- company_name: RAPT Therapeutics, Inc.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1673772/000119312526015882/0001193125-26-015882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1673772/000119312526015882/d12800d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-015882
- JSON: https://secwatch.observer/filing/0001193125-26-015882.json
- Plain text: https://secwatch.observer/filing/0001193125-26-015882.txt

## Key facts
- Material Agreements
  RAPT Therapeutics, Inc. entered into Merger Agreement with GlaxoSmithKline LLC, Redrose Acquisition Co., GSK plc (effective 2026-01-19).
  - Action: entry
  - Agreement: merger
  - Counterparty: GlaxoSmithKline LLC, Redrose Acquisition Co., GSK plc
  - Effective: 2026-01-19
  source text: RAPT Therapeutics, Inc., a Delaware corporation (the “ Company ” or “ RAPT Therapeutics ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, GlaxoSmithKline LLC, a Delaware limited liability company (“ Parent ”), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”) and, solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales (“ Ultimate Parent ” or “ GSK ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1673772/000119312526015882/0001193125-26-015882-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.